Hyperkalemia
📧 Sign up to get email alerts when something new happens for Hyperkalemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-04-30Clinical Trial Update: Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia [Phase 4]
A Phase 4 clinical trial at Nantes University Hospital is evaluating insulin dextrose infusion, nebulized salbutamol, and their combination …
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects [Phase 1]
Phase 1 trial assessing the effect of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin in healthy subjec…
-
CLINICAL_TRIALS trial_result · 2024-02-26Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. [Phase 2]
Phase 2 clinical trial update evaluating the safety and efficacy of WS016 in patients with hyperkalemia.
-
FDA approval · 2024-02-08FDA Approved: LOKELMA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for LOKELMA (sodium zirconium cyclosilicate) from AstraZeneca, indicating an update or expansion to …
-
CLINICAL_TRIALS trial_result · 2023-10-06Clinical Trial Update: Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease [Phase 3]
Phase 3 trial investigating SZC for effects on serum potassium and bicarbonate in patients with hyperkalemia and metabolic acidosis related …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-10-02FDA Approved: VELTASSA — Supplemental Application (Vifor Pharma, Inc.)
FDA approved a supplemental application for VELTASSA (patiromer) submitted by Vifor Pharma, Inc.
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management [Phase 4]
Phase 4 clinical trial update on patiromer as an adjunct for urgent hyperkalemia management has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia [Phase 3]
Phase 3 trial comparing ZG-801 to placebo in hyperkalemia completed.
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects [Phase 3]
Phase 3 trial assessing sodium zirconium cyclosilicate to reduce pre-dialysis hyperkalemia in Chinese subjects has completed with results po…
-
FDA approval · 2023-03-27FDA Approved: VELTASSA — Supplemental Application (Vifor Pharma, Inc.)
FDA approved a supplemental application for VELTASSA (patiromer) submitted by Vifor Pharma, Inc., formalizing updates to the product labelin…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients [Phase 4]
Phase 4 clinical trial evaluating how patiromer affects the pharmacokinetics of immunosuppressive drugs in kidney transplant recipients.
-
CLINICAL_TRIALS trial_result · 2023-03-22Clinical Trial Update: The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia [Phase 2]
Phase 2 trial investigating the effects of patiromer on serum potassium and gut microbiome in patients with end-stage renal disease and hype…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) [Phase 3]
Phase 3 clinical trial DIAMOND evaluating patiromer for managing hyperkalemia in patients on RAAS inhibitors for heart failure has completed…
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia [Phase 4]
Phase 4 trial update comparing SZC with enhanced nutrition advice versus standard of care in dialysis patients with hyperkalemia; study term…
-
FDA approval · 2022-10-18FDA Approved: KIONEX — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for KIONEX (sodium polystyrene sulfonate) from ANI Pharmaceuticals, Inc.
-
FDA approval · 2022-10-17FDA Approved: CALCIUM GLUCONATE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for CALCIUM GLUCONATE from Fresenius Kabi USA, LLC.
-
FDA approval · 2022-09-30FDA Approved: LOKELMA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA has approved a supplemental application for Lokelma (sodium zirconium cyclosilicate) from AstraZeneca Pharmaceuticals LP.
-
CLINICAL_TRIALS trial_result · 2022-09-26Clinical Trial Update: Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia [Phase 2]
Phase 2 trial evaluating pharmacodynamics and safety of patiromer in children and adolescents with chronic kidney disease and hyperkalemia; …
-
CLINICAL_TRIALS trial_result · 2022-05-19Clinical Trial Update: Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy [Phase 3]
A Phase 3 trial reports that Sodium Zirconium Cyclosilicate lowers hyperkalemia after parathyroidectomy.
-
CLINICAL_TRIALS trial_result · 2022-05-16Clinical Trial Update: Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On [Phase 4]
Phase 4 clinical trial evaluating mineralocorticoid receptor antagonism as an add-on in atherosclerosis has been terminated with results pos…
-
CLINICAL_TRIALS trial_result · 2022-05-04Clinical Trial Update: A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia [Phase 2]
Phase 2 study completed evaluating RDX013 for hyperkalemia, assessing safety and efficacy.
-
CLINICAL_TRIALS trial_result · 2021-12-30Clinical Trial Update: Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects. [Phase 4]
Clinical trial update comparing levalbuterol to albuterol on cardiac side effects and potassium lowering effects in hyperkalemia; phase 4 st…
-
FDA approval · 2021-12-22FDA Approved: VELTASSA — Supplemental Application (Vifor Pharma, Inc.)
The FDA approved a supplemental application for VELTASSA (patiromer) from Vifor Pharma, Inc., resulting in an updated labeling for the produ…
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet. [Phase 4]
Phase 4 clinical trial evaluating patiromer to facilitate transitioning chronic kidney disease patients with hyperkalemia to a plant-rich di…
-
FDA approval · 2021-05-14FDA Approved: VELTASSA — Supplemental Application (Vifor Pharma, Inc.)
The FDA has approved a supplemental application for VELTASSA (patiromer) filed by Vifor Pharma, Inc.